The U.S. Intravenous Immunoglobulin Market plays a crucial role in treating immunodeficiency diseases and various autoimmune disorders, reflecting a steady evolution influenced by advanced therapies ...

The intravenous route was the most common route of immunoglobulin administration (n = 32), followed by the conventional subcutaneous (n = 16) and facilitated subcutaneous (n = 10) routes.

Sanofi's antibody riliprubart has received orphan drug designation from Japan's MHLW for its potential to treat CIDP.

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

Gammagard Liquid ERC is a ready-to-use formulation with low IgA content designed to ease administration burden by removing the need to reconstitute.

It is the only ready-to-use liquid immunoglobulin therapy with (IgA) content and is set for commercialization in 2026.

Prince Edward Island’s Chief Public Health Office says a total of 15 people have now been identified as at risk after ...

The province's Chief Public Health Office has identified between four and eight infants who require medication to protect ...

Bharat Serums and Vaccines has received approval from the Subject Expert Committee (SEC) functional under the Central Drugs ...

The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...